Mechanism of action<unk>  is a biologic agent, a recombinant modified version of human activated factor X (FXa).<unk>  differs from native FXa due to the removal of a 34 residue fragment that contains the Gla domain. This modification reduces<unk> 's procoagulant potential. Additionally, a serine to alanine (S419A) mutation in the active site eliminates its activity as a prothrombin to thrombin catalyst, but still allows the molecule to bind to FXa inhibitors. FXa inhibitors bind to<unk>  with the same affinity as to natural FXa. As a consequence in the presence of<unk>  natural FXa is partially freed, which can lead to effective hemostasis. In other words, it acts as a decoy receptor.<unk>  reverses effect of all anticoagulants that act directly through FXa or by binding antithrombin III. The drug is not effective against factor IIa inhibitor dabigatran.
Andexanet alfa
Vonicog alfa
Efgartigimod alfa
Crofelemer
Damoctocog alfa pegol
Bulevirtide
Fludroxycortide
Clinatec